يعرض 3,141 - 3,160 نتائج من 21,342 نتيجة بحث عن '(( significant decrease decrease ) OR ( significance ((a decrease) OR (teer decrease)) ))', وقت الاستعلام: 0.49s تنقيح النتائج
  1. 3141

    UTI diagnoses by sex and physician specialty (2013–2019). حسب Thomas Hanslmeier (19949694)

    منشور في 2024
    الموضوعات: "…fluoroquinolone shares decreased…"
  2. 3142
  3. 3143

    Fig 3 - حسب Razieh Bidhendi-Yarandi (7139387)

    منشور في 2025
    الموضوعات:
  4. 3144

    Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

    منشور في 2024
    "…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …"
  5. 3145

    Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

    منشور في 2024
    "…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …"
  6. 3146
  7. 3147
  8. 3148

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  9. 3149

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  10. 3150

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  11. 3151

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  12. 3152

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  13. 3153

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  14. 3154

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  15. 3155

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

    منشور في 2025
    "…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
  16. 3156
  17. 3157
  18. 3158
  19. 3159
  20. 3160